Market revenue in 2023 | USD 1.6 million |
Market revenue in 2030 | USD 15.4 million |
Growth rate | 38.5% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 81.25% in 2023. Horizon Databook has segmented the Canada live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
According to Crohn’s and Colitis Canada, IBD is increasing rapidly in the country. For instance, Crohn’s and Colitis Canada mentioned IBD prevalence has increased from an estimated 270,000 in 2018 to 322,600 diagnosed cases in Canada in 2023. In addition, by 2035, the IBD ratio is estimated to be 1 in 91 Canadians, and in 2023, this number is already 1 in 88 seniors.
This increased incidence of IBD in Canada is due to the rapid rise of new cases and aging population & new diagnoses among seniors. Therefore, growing hospitalization has certainly resulted in substantial morbidity and mortality, creating a requirement for effective biotherapeutics to reduce recurrent diseases in patients.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Canada live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account